Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Stock Now Rated “Buy” by Sell-Side Analysts

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) has been assigned a consensus rating of “Buy” from the ten analysts that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, seven have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $15.86.

IVA has been the topic of a number of research analyst reports. Truist Financial lifted their target price on Inventiva from $13.00 to $18.00 and gave the company a “buy” rating in a research report on Friday. Cantor Fitzgerald began coverage on Inventiva in a report on Friday, July 17th. They set an “overweight” rating for the company. Wall Street Zen raised shares of Inventiva from a “sell” rating to a “hold” rating in a research report on Saturday. Piper Sandler reaffirmed an “overweight” rating on shares of Inventiva in a research note on Wednesday, September 16th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a research note on Friday, July 17th.

Institutional Trading of Inventiva

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. NEXTBio Capital Management LP acquired a new position in Inventiva in the 4th quarter valued at about $6,039,000. Propel Bio Management LLC acquired a new stake in Inventiva during the 4th quarter worth approximately $4,650,000. Eventide Asset Management LLC purchased a new position in Inventiva in the 4th quarter valued at approximately $1,155,000. Seven Fleet Capital Management LP purchased a new position in Inventiva in the 1st quarter valued at approximately $1,111,000. Finally, Persistent Asset Partners Ltd acquired a new position in shares of Inventiva in the fourth quarter worth $603,000. Hedge funds and other institutional investors own 19.06% of the company’s stock.

Inventiva Stock Down 2.2%

Shares of Inventiva stock opened at $3.48 on Thursday. Inventiva has a twelve month low of $3.11 and a twelve month high of $7.98. The firm’s 50-day moving average price is $4.30 and its 200 day moving average price is $4.64.

Inventiva (NASDAQ:IVA) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.14) EPS for the quarter. The company had revenue of $0.75 million during the quarter. As a group, analysts anticipate that Inventiva will post -0.81 earnings per share for the current year.

Inventiva Company Profile

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Dijon, France. The company develops oral small-molecule therapies for chronic metabolic and autoimmune diseases, with a focus on conditions that have limited treatment options.

Inventiva’s lead product candidate is lanifibranor, an investigational pan-PPAR agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders.